Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab vs Lenalidomide in Newly Diagnosed Multiple Myeloma After ASCT
NCT05317416Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Mar 2022; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05317416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317416.